title: Platelet activating factor (PAF) stimulates release of PGI2 from inflamed rabbit gallbladder cell cultures.
abstract: This study examines the hypothesis that PAF stimulates release of PGI2 from inflamed rabbit gallbladder explant cell cultures. New Zealand white rabbits underwent bile duct ligation for 72 h (72 h BDL), or sham operation, Sham and 72 h BDL gallbladder explants were placed in culture, and the cells grown to 75% confluence. The cells were exposed to increasing concentrations of PAF for 60 min. The media analyzed for eicosanoid release by EIA and the cells analyzed for cyclooxygenase and prostacyclin synthase content by immunoblot analysis. PAF increased release of 6-keto-PGF1 alpha from the 72 h BDL gallbladder cell cultures in a dose-related manner which was inhibited by indomethacin preincubation by 90%. The increased 72 h BDL cell release of 6-keto-PGF1 alpha was not associated with changes in the content of cyclooxygenase or prostacyclin synthase. PAF did not alter eicosanoid release from sham control cell cultures. These data suggest that PAF can only up-regulate endogenous 6-keto-PGF1 alpha release from the 72 h BDL cells that had been previously stimulated by inflammation. PAF may thus contribute to gallbladder distention and injury by chronic stimulation of inflamed gallbladder PGI2 release.
authors.affiliation: Department of Surgery, University of Texas Southwestern Medical Center, Dallas 75235, USA.
authors.forename: S I
authors.initials: SI
authors.lastname: Myers
authors.forename: R
authors.initials: R
authors.lastname: Turnage
authors.forename: K
authors.initials: K
authors.lastname: Kadesky
authors.forename: L
authors.initials: L
authors.lastname: Bartula
authors.forename: A
authors.initials: A
authors.lastname: Riva
authors.forename: B
authors.initials: B
authors.lastname: Kalley-Taylor
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism*; D000818:Animals; D000906:Antibodies; D002478:Cells, Cultured; D002764:Cholecystitis / Q000188:drug therapy / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000378:metabolism*; D005704:Gallbladder / Q000378:metabolism / Q000473:pathology*; D015151:Immunoblotting; D007213:Indomethacin / Q000494:pharmacology; D019746:Intramolecular Oxidoreductases; D007535:Isomerases / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D011506:Proteins / Q000032:analysis; D011817:Rabbits; D013929:Thromboxane B2 / Q000378:metabolism
chemical_list: D000906:Antibodies; D010972:Platelet Activating Factor; D011506:Proteins; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D003577:Cytochrome P-450 Enzyme System; D015237:Dinoprost; D011464:Epoprostenol; D011451:Prostaglandin-Endoperoxide Synthases; D007535:Isomerases; D019746:Intramolecular Oxidoreductases; C022461:prostacyclin synthetase; D007213:Indomethacin